Healthcare Business Update: WellPoint DELAYS 2013 Guidance, Endo Health’s Subsidiary RECALL

Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) United Kingdom subsidiary introduces Tolterodine, which is a generic version of Detrusitol from Pfizer Inc. (NYSE:PFE). The medication is used for the symptomatic treatment of urge incontinence along with overactive bladder syndrome.

Don’t Miss: Proctor & Gamble’s Research Woes Take a Toll on Profits.

Insurer WellPoint, Inc. (NYSE:WLP) shares dip on comments made on Monday at Morgan Stanley’s healthcare conference, during which Chief Financial Officer Wayne DeVeydt said that the company is not yet ready to provide guidance for its 2013 results. DeVeydt pointed to difficulties with its commercial business, along with changes linked to the Affordable Care Act.

Endo Health Solutions Inc. (NASDAQ:ENDP) reports that a subsidiary has issued a voluntary recall for one lot of its hydrocodone bitartrate and acetaminophen tablets, explaining that it is possible that some tablets exceed the weight specification and thus could be super-potent. The increased acetaminophen content could cause liver toxicity, especially in patients taking other acetaminophen containing medications, those suffering from liver dysfunction, or persons who consume in excess of 3 alcoholic beverages daily.

Don’t Miss More Hot Stories by Wall St. Cheat Sheet:

Is Apple’s Stock a BUY at Today’s Price?
Will This Move Help Zynga Win Back Users (And Shareholders)?
This is How Sprint is Preparing for the New iPhone